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Abstract Both appropriate DNA methylation and histone
modifications play a crucial role in the maintenance of
normal cell function and cellular identity. In cancerous cells
these “epigenetic belts” become massively perturbed,
leading to significant changes in expression profiles which
confer advantage to the development of a malignant
phenotype. DNA (cytosine-5)-methyltransferase 1 (Dnmt1),
Dnmt3a and Dnmt3b are the enzymes responsible for
setting up and maintaining DNA methylation patterns in
eukaryotic cells. Intriguingly, DNMTs were found to be
overexpressed in cancerous cells, which is believed to
partly explain the hypermethylation phenomenon commonly
observed in tumors. However, several lines of evidence
indicate that further layers of gene regulation are critical
coordinators of DNMT expression, catalytic activity and
target specificity. Splice variants of DNMT transcripts have
been detected which seem to modulate methyltransferase
activity. Also, the DNMT mRNA 3′UTR as well as the
coding sequence harbors multiple binding sites for trans-
acting factors guiding post-transcriptional regulation and
transcript stabilization. Moreover, microRNAs targeting
DNMT transcripts have recently been discovered in normal
cells, yet expression of these microRNAs was found to be
diminished in breast cancer tissues. In this review we
summarize the current knowledge on mechanisms which
potentially lead to the establishment of a DNA hyper-
methylome in cancer cells.
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Abbreviations
3′UTR 3′ untranslated region
CDS Coding sequence
CpG Cytosine-phosphate-guanine dinucleotide
DNMT DNA (cytosine-5)-methyltransferase
ER Estrogen receptor
HDAC Histone deacetylase
ICF Immunodeficiency, centromere instability and
facial abnormalities
HuR ELAV (embryonic lethal, abnormal vision,
Drosophila)-like 1 (Hu antigen R)
MBD Methyl-CpG binding domain protein
miRNA microRNA
PgR Progesterone receptor
RISC RNA induced silencing complex
UTR Untranslated region
Introduction
The molecular mechanisms underlying the development
and progression of breast cancer are far from being
understood. It is evident that the initiation of breast cancer
as well as its transition towards distinct breast cancer
subtypes is triggered by the accumulation of pathologically
altered gene function. Like in other cancers, the increasing
number of deregulated genes subsequently affects virtually
any important cellular network, such as cell cycle control,
apoptosis, DNA repair, detoxification, inflammation, cell
adhesion or migration. According to the somatic mutation
theory cancer has long been considered as a genetic
disorder of fatal acquisition of multiple mutations in key
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DOI 10.1007/s10911-010-9165-1genes, which coordinate these functional networks. Such
mutations can result either in inactivation of tumor sup-
pressor genes (e.g. TP53, BRCA1) or activation of proto-
oncogenes (e.g. MYC), both of which contributes to the
malignant state of a transformed cell.
During the past decade, the somatic mutation theory of
cancer has been revolutionized for it became evident that
epigenetic malfunction plays a role as equally important as
genetics in cancer development. The concept of epigenetics
describes mitotically stable states and changes of gene
activity that do not involve alterations of the primary DNA
sequence, thus provide a second layer of information above
the pure genomic blueprint [1]. Epigenetic mechanisms
coordinate crucial biological processes, like X-chromosome
inactivation, genomic imprinting, position effect variega-
tion, reprogramming of genomes during differentiation and
development, or RNA interference leading to posttranscrip-
tional gene silencing. It is not surprising that defects in the
dynamics of these key functions were found to be
associated with many human disorders, including breast
cancer (for review see [2]). In recent years, two epigenetic
mechanisms have emerged as the most critical players of
transcriptional regulation: The methylation of DNA and
chemical histone tail modifications. DNA methylation
refers to the covalent post-replicative addition of a methyl
group (–CH3) onto the 5-carbon of the cytosine ring within
CpG dinucleotides. This enzymatic reaction is conferred by
DNA methyltransferases (DNMT), which catalyze the trans-
fer from the methyl group donor S-adenosyl methionine.
Typically, such CpG dinucleotides are enriched in gene
promoters or the first exon where they cluster to form a so-
called CpG island. Approximately 60% of protein-coding
mammalian genes harbor CpG islands in their promoter
region. These are normally unmethylated in transcriptionally
activegeneslikehousekeepinggenes,whereasdevelopmental
and tissue-specific genes mostly appear to be methylated and
silenced in differentiated tissues (e.g. reviewed in [3, 4]). In
cancer, however, numerous genes which are unmethylated
in the non-malignant tissue become aberrantly methylated in
the tumor. Since the first discovery of a hypermethylated
gene in cancer, the retinoblastoma tumor suppressor (RB1)
[5], many tumor suppressor genes have been identified being
hypermethylated in tumorous tissues as compared to their
normal counterparts, e.g. VHL, CDKN2A,o rBRCA1 [6–8].
Although our knowledge on epigenetically inactivated genes
in cancer is constantly increasing, the basic mechanisms
underlying aberrant DNA methylation as well as the selec-
tion of genes that become methylated are only rudimentary
understood, and shall be reviewed further on.
The second key player in chromatin conformation and
transcriptional regulation are histone modifications. Histone
proteins constitute the nucleosome around which DNA is
tightly packaged. Their N-terminal tails reach out of the
nucleosomal core and harbor numerous spots for protein
modifications, such as acetylation, methylation, phosphor-
ylation, sumoylation, ubiquitination or ADP ribosylation
(reviewed in [9, 10]). Both the type of modification and the
affected amino acid residue determine the tightness of the
DNA-histone interaction, leading to either an open chro-
matin state allowing active transcription (e.g. acetylation of
lysine) or to a compact chromatin state associated with
transcriptional repression (e.g. deactetylation of the same
residue). Altered histone modifications in breast cancer will
be reviewed in a further article of this issue, but one essen-
tial relationship ought to be mentioned: DNA methylation
and histone modifications interact with each other in the
regulation of gene expression. It is generally believed that
DNA methylation is the initiating event that marks certain
genomic sites for the establishment of a transcriptionally
inactive chromatin state [11, 12]. DNA methylation, how-
ever, may also depend on prior methylation of histone 3 at
lysine 9 (H3K9) [13], and is followed by binding of methyl-
CpG binding domain proteins (MBDs) which contribute to
gene repression by the recruitment of histone deacetylases
(HDACs) to the nucleosome [14, 15]. Also, for certain genes
it has been shown that the initial recruitment of DNMTs to
target sequences is mediated by Enhancer of zeste homo-
logue 2 (EZH2) as a part of the repressive polycomb group
(PcG) of proteins [16, 17], increasing the complexity of
relations between various epigenetic repression systems.
In recent years, the discovery of a class of small non-
coding RNAs, so called microRNAs (miRNAs), has gained
much attention in oncological research. MiRNAs are
regulatory RNAs 20–30 nucleotides in length, that perfectly
match the 3′ untranslated regions (3′UTR) of target
mRNAs, resulting in its degradation or inhibition of mRNA
translation (reviewed in [18]). It is the function of the target
mRNA that determines a miRNA acting either tumor
suppressive (if directed against proto-oncogene transcripts)
or oncogenic (if directed against tumor suppressor gene
transcripts). Prominent members of miRNAs include the
let-7 family (containing at least 11 homologous miRNAs),
whose depletion in breast, lung and colon cancer causes
enhanced tumorigenicity [19–21]. Another example is
miR-21, whose overexpression in breast cancer confers
increased invasion capacities and promotes tumor metas-
tasis to the lung [22, 23]. The number of genes known to
beregulatedbymiRNAs isgrowingrapidly.The latestrelease
of the Sanger miRNA registry currently annotates more than
800 human miRNAs (http://microrna.sanger.ac.uk;r e l e a s e
13.0), yet many more miRNAs are expected to be identified
in the future. It is not surprising that miRNAs, just like
protein-coding genes, have to be tightly regulated in order to
contribute to a distinct transcriptome of a normal cell. In
cancer, however, miRNAs were found to be massively
deregulated. Recent genome-wide approaches revealed that
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Signatures of deregulated miRNAs were shown to be useful
in subtyping mammary carcinomas [24, 25], or determining
their aggressiveness, e.g. in node-negative estrogen receptor-
positive tumors [26]. Like protein-coding genes, DNA
sequences encoding miRNAs were found to be a target of
aberrant DNA methylation [27], explaining in part how
miRNAs may be upregulated (through DNA hypomethyla-
tion) or downregulated (through DNA hypermethylation) in
cancer. Besides DNA methylation, a failure of post-
transcriptional regulation may also lead to impaired miRNA
biogenesis, as has been shown for the miRNA maturation
responsible endoribonuclease Dicer, which is commonly
expressed at lower levels e.g. in progressive breast cancer
[28]. The production of mature miRNAs underlies a
complex process of subsequent modifications of the primary
transcript, termed pri-miRNA. The primary transcript con-
tains a stem-loop structure representing the active miRNA
species. This stem-loop is liberated by the nuclear ribonu-
clease III Drosha, and then termed premiRNA. After export
to the cytoplasm the precursor miRNA is further processed
by the ribonuclease Dicer, resulting in the mature miRNA.
Finally, this miRNA is loaded into the RNA induced
silencing complex (RISC) where it exhibits translational
repression of its target mRNA [29–31]. In tumourous cells,
discrepancies between the levels of primary transcript,
precursor and mature miRNA have been reported, strongly
arguing for defects in the maturation pathways of miRNAs on
variouslevels,suchasDroshaorDicerprocessing[32–34]. In
the second part of this article the current knowledge on
defects in miRNA processing shall be highlighted.
Mechanisms of Altered DNA Methylation
DNA methylation patterns differ largely between tumor
tissues and corresponding normal tissues. A paradoxon
commonly observed in carcinomas is that despite of the
regional hypermethylation of tumor suppressor genes, the
global 5-methylcytosine content is drastically decreased in
the bulk of the tumor genome. Less frequent than regional
DNAhypermethylation,alsoregionalDNAhypomethylation
occurs in cancer, resulting in the activation of potential
oncogenes [35]. The existence of a specific enzyme con-
ferring active demethylation of methylated DNA is still
unclear. However, enzymes conferring methylation of DNA
have been well characterized.
DNA Methyltransferases
The C-terminal catalytic domain of DNMTs transfers
methyl groups onto cytosine residues within the DNA, thus
methyltransferases represent the crucial enzyme class
responsible for hypermethylation of tumor suppressor
genes. In mammals, five members of the DNMT protein
family have been discovered (Dnmt1, Dnmt2, Dnmt3a,
Dnmt3b, and Dnmt3L), of which only three were shown to
possess catalytic methyltransferase activity (Dnmt1, Dnmt3a,
and Dnmt3b). Dnmt1 exhibits a strong preference for hemi-
methylated over unmethylated DNA, and its particular
targeting of replication foci, as shown by co-localization with
the proliferating cell nuclear antigen (PCNA), is thought to
allow copying of the parental DNA methylation pattern onto
the newly synthesized DNA daughter strand [36]. Therefore,
Dnmt1 is regarded as a maintenance methyltransferase. The
Dnmt3 family consists of two catalytic members, Dnmt3a
and Dnmt3b, both of which exhibit increased methyltrans-
ferase activity towards unmethylated over hemi-methylated
DNA, which is why they were termed de novo methyl-
transferases. DNMT3A -/- knock-out mice appear to be
normally developed, but die shortly after birth. Homozygous
inactivation of DNMT3B leads to embryonic lethality due
to multiple developmental disorders including growth
impairment and rostral neural tube defects [37]. In
humans, a specific mutation in the DNMT3B gene is
responsible for a syndrome referred to as ICF (Immuno-
deficiency, Centromere instability and Facial abnormali-
ties), which is characterized by global hypomethylation of
centromeric DNA repeat sequences, chromatin deconden-
sation and genomic instability in tissues of affected
patients [38–41]. The remaining members of the DNMT
family, Dnmt2 and Dnmt3L, lack cytosine methyltransfer-
ase activity, although Dnmt3L was shown to be capable of
stimulating de novo DNA methylation mediated by
Dnmt3a [42, 43].
DNA Hypomethylation in Breast Cancer
Among solid tumor types, global DNA hypomethylation in
most evident in breast cancer with up to 50% of cases
showing reduced 5-methylcytosine content when compared
with normal tissue counterparts [44, 45]. Hypomethylation
in breast carcinomas mainly affects repetitive DNA sequen-
ces and pericentromeric satellite DNA, which are normally
heavily methylated in non-malignant cells [44, 46]. For
instance, long interspersed nuclear elements (LINEs)
represent retrotransposons that are methylated in all
mammalian cell types. Cancer-related hypomethylation of
these transposable elements induces transcriptional reacti-
vation, thus they can relocate and integrate into other sites
of the genome, leading to insertional mutagenesis and
contributing to genomic instability [47]. Hypomethylation
of the Sat2 and Satα repeats frequently occurs in certain
cancers, such as ovarian and breast cancer [48, 49]. In the
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SatR-1 hypomethylation 86% of breast tumors [49, 50]. In
contrast to ovarian cancer, where increased satellite DNA
hypomethylation is associated with tumor progression [48],
satellite DNA hypomethylation in breast cancer is involved
in early tumor development [49].
Though being a relatively rare event, DNA hypomethyl-
ation can also affect individual genes. In breast cancer, this
i st h ec a s ef o rt h em e l a n o m aa ssociated cancer/testis
antigens MAGE, which are methylated and silenced in
adult tissues, but hypomethylated and expressed in several
tumors and breast cancer cells [51]. Other hypomethylated
genes in breast tumors include the gene encoding the
plasminogen activator uPA (PLAU), the breast cancer
specific protein 1/synuclein-γ gene (SNCG), and more
recently reported, the multidrug resistance 1 gene (MDR1)
[52–54].
The underlying mechanisms leading to DNA hypo-
methylation in cancer have not yet been clearly elucidated.
There is no reduction of DNA methyltransferase activity in
cancer cells [55]. Despite, in animal models knockdown or
deficiencies in the activities of DNMTs lead to genome-
wide DNA hypomethylation and chromosomal instability
[56]. Reports from hepatocellular carcinoma and leukaemia
suggested that enzymatically inactive DNMTsplice variants
compete with enzymatically active forms for the same
binding site of pericentromeric satellite DNA, thereby
inhibiting DNA methylation [57, 58]. However, this
association could not be confirmed in other tumor types
[59], so further investigations are needed.
De Novo Gene Methylation is a Non-random Process
As stated before, many unmethylated tumor suppressor
genes in normal tissues acquire hypermethylation during
tumor development, so the key question here is: does
aberrant hypermethylation of genes in cancer follow a
random process that is accompanied by clonal selection of
those cells which gained growth advantages, or do DNMTs
specifically recognize target genes, which implies that the
repertoire of potential targets for inactivation is already
encoded by intrinsic or extrinsic factors?
Currently, research results seem to support the latter
hypothesis. First to mention, it was shown that distinct
tumor types may harbor methylation in several common
genes, but also in numerous different genes. This finding
lead to the first hypermethylation profiles of human cancer.
The analysis of 12 tumor suppressor genes in 600 primary
tumors representing 15 tumor entities revealed tumor-
characteristic methylation changes in all genes, displaying
a unique profile of promoter methylation for each cancer
type, in which some gene changes were shared and others
were cancer type-specific [60]. As an example, the genes
encoding secreted frizzled-related proteins (SFRP) 1 and 2,
both encoding inhibitors of the Wnt signaling pathway,
were found to be high-frequently methylated in virtually
any human tumor type, including breast and colon cancer
[61–64]. Furthermore, SFRP methylation occurs already in
early tumor stages, suggesting that epigenetic inactivation
of SFRP genes may be a common hallmark of human
neoplasia following non-random but targeted gene selec-
tion. Second, specific nucleotide sequence patterns within
gene promoters were identified that are more prone to
hypermethylation than other sequences, which tend to be
methylation-resistant. Feltus and co-workers have demon-
strated in an ectopic Dnmt1 overexpression model that CpG
islands differ in their susceptibility to de novo methylation,
suggesting the existence of cis-acting intrinsic factors that
facilitate methylation of specific target sequences [65].
Indeed, in a further study Feltus and colleagues were able to
identify 13 short DNA sequence patterns between 11 bp
and 37 bp in length, which were able to distinguish between
methylation-prone and methylation-resistant promoters with
87% accuracy [66]. Interestingly, only the methylation-
prone DNA sequences were closely associated with CpG
islands, whereas methylation-resistant sequences were
randomly distributed along the analyzed chromosome,
further supporting the idea of an intrinsic hypermethylation
code in the DNA sequence of affected gene promoters.
However, this study used a model of Dnmt1 overexpres-
sion, which exerts only limited de novo methylation
capacity. It remains to be shown whether Dnmt3a or
Dnmt3b overexpression models may also identify similar
methylation-prone DNA sequences in the mammalian
genome.
At least in part, another finding supports the hypothesis
that aberrant de novo methylation is a non-random process.
It has been recently demonstrated that chromatin repressive
proteins, such as PcG, can mark certain target genes for
hypermethylation by DNMTs. In an approach to identify
the functional relation between DNMTs and EZH2, Vire
and colleagues showed that the presence of EZH2 is tightly
associated with the presence of Dnmt1, Dnmt3a and
Dnmt3b proteins at gene promoters, e.g. those of the
MYT1 or KCNA1 gene [16]. They found that after siRNA-
mediated depletion of EZH2 expression DNMTs were no
more bound to the respective promoters, while depletion of
DNMT expression did not prevent EZH2 from endowing
target sequences with the repression mark H3K27. In
another study, Schlesinger and co-workers investigated
whether the H3K27 mark is specifically associated with
de novo methylated CpG islands in the colon tumor cell
line Caco-2. Supporting the previous idea, all analyzed
genes found to be hypermethylated in the cell line were also
found being enriched for H3K27 [17]. Interestingly, the
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in the tumor cells themselves, but already existed in normal
control tissues, as determined by chromatin immunoprecip-
itation (ChIP) analysis using an antibody against trimeth-
ylated H3K27. Since unmethylated control genes in normal
tissues, such as blood lymphocytes, embryonic stem cells
and fibroblasts were lacking this histone mark, it is
conceivable that a subset of target genes may first become
“primed” by the H3K27 mark through EZH2 in normal
tissues, which then could represent a favored substrate for
hypermethylation during cancer development. Among the
identified PcG target genes were the previously mentioned
SFRP1 and SFRP2 gene, suggesting that EZH2-mediated
de novo methylation may be affecting in particular develop-
mental regulator genes that are occupied by polycomb
repressor complexes in embryonic stem cells [67, 68],
increasing their susceptibility to non-random methylation-
mediated silencing in cancer.
DNMTs are Differentially Expressed in Human Cancer
DNMTs are ubiquitously expressed at distinct levels in
normal human tissues [69]. In cancer, they are overex-
pressed in various tumor types, e.g. in leukemia, colorectal
cancer, prostate cancer, ovarian cancer, endometrial cancer
and breast cancer [55, 70–75]. Surprisingly, the mean levels
of Dnmt1, Dnmt3a and Dnmt3b overexpression turned out
to be quite similar among different tumor types. However,
these levels were not strikingly high, ranging from 1.8 to
2.9-fold in breast cancer up to 4-fold in colon cancer. In
breast cancer, approximately 30% of patients revealed
overexpression of Dnmt3b in the tumor tissue as compared
to normal breast tissue. Taken only these overexpressing
tumors into account, the Dnmt3b expression change was
82-fold, thus being significantly higher [55]. Interestingly,
Dnmt1 and Dnmt3a were overexpressed in only 5% and 3%
of breast carcinomas, exhibiting also a lower expression
change of 17- and 14-fold in the affected tumors,
respectively. These results have two implications: First, it
appears that Dnmt3b plays the predominant role over
Dnmt3a and Dnmt1 in breast tumorigenesis. This is
consistent with a recent study in breast cancer cell lines,
which demonstrated a strong correlation between total
DNMT activity and overexpression of Dnmt3b, but not
with the expression of Dnmt3a or Dnmt1 [76]. Second, it is
noteworthy that due to the lack of a specific antibody
against Dnmt3b almost any expression analysis so far has
been performed on the RNA level. Only recently, a study
on colon cancer employing 765 primary colorectal carci-
nomas revealed that Dnmt3b protein overexpression affects
15% of cases [77], in consistency with the relatively low
frequency of overexpression reported in other tumor types.
The fact that only a subgroup of tumors is affected by
Dnmt3b overexpression raises the question whether this can
be regarded as a universal feature of tumorous cells. In
general, it is possible that further regulators of DNMT
activity may play an important role in the dysfunction of
the DNA methylation machinery. For instance, DNMT
target sequence specificity may be impaired by genetic or
regulatory factors, such as DNMT-associated proteins or
protein complexes in which DNMTs reside. Furthermore,
DNMT3B is the only DNA methyltransferase whose mRNA
is expressed as several alternative splice variants. Although
DNMT3B1 and DNMT3B3 are the most abundantly
expressed transcripts, only DNMT3B1 and DNMT3B2 were
shown to be catalytically active, while the remaining splice
variants do not possess methyltransferase activity due to the
lack of a C-terminal catalytic domain [69, 78]. Despite this,
Ostler et al. identified over 20 novel DNMT3B transcripts
from various cancer cell lines that are aberrantly spliced at
the 5′-end and lacked the C-terminal catalytic domain.
Surprisingly, forced expression of one of the variant
transcripts (DNMT3B7) significantly changed the DNA
methylation pattern in kidney HEK293 cells [79]. Since no
catalytic domain could be responsible for the DNA
methylation changes, it was proposed that the truncated
Dnmt3b7 protein could interfere with DNA methylation
processes by binding of Dnmt3b interaction partners, or
that the truncated version of DNMT3b affects the activity
of catalytic DNMTs by directly binding to the DNA.
Adding more complexity to this, the catalytically inactive
Dnmt3L directly binds Dnmt3b and positively stimulates its
methylation activity [80]. Taking into account the large
number of physiological and aberrant splice variants of the
DNMT3B transcript, it can only be speculated that the
precise mechanisms of Dnmt3b action and the biological
function of the many diverse transcripts still have to be
identified.
Despite the low-frequent overexpression of DNMTs in
tumors, a direct evidence for Dnmt3b involvement in
cancer has been previously described. Soejima and
colleagues demonstrated that Dnmt3b contributes to the
oncogenic phenotype in a lung cancer model. In their study,
Dnmt3b was able to promote oncogenic transformation
induced by SV40 T antigen in bronchial epithelial cells,
whereas antisense suppression of Dnmt3b prevented tumor
growth in soft agar assays [81]. In a study on colon
tumorigenesis the impact of a conditional inactivation of
DNMT3B in APC
Min/+ mice was investigated. Although
loss of Dnmt3b expression had no impact on micro-
adenoma formation, it significantly decreased the formation
of macroscopic colonic adenomas, suggesting a role of
Dnmt3b in the transition from one to the other stage [82]. In
breast cancer, elevated expression of Dnmt3b was shown to
be significantly associated with higher histological grade,
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proliferation marker Ki67, pointing to a potential involve-
ment of Dnmt3b in breast tumor progression and aggres-
siveness [55]. In the same study, an association of high
Dnmt3b expression and reduced relapse-free patient sur-
vival was detected, although it was only significant in a
subgroup of patients receiving adjuvant hormone therapy,
while in patients receiving adjuvant chemotherapy no
difference could be detected.
A question of particular interest here is: Is a more
malignant phenotype, which seems to be associated with
higher Dnmt3b expression, indeed related to increased
hypermethylation of genes in these tumors? The answer to
this is still not clear. While clear associations have been
demonstrated in some in vivo studies, in other studies this
relationship could not be confirmed. For instance, in
colorectal tumors no significant correlation could be found
between the level of Dnmt3b overexpression and the
methylation status of the four indicator genes adenomatous
polyposis coli (APC), estrogen receptor α (ESR1), cyclin-
dependent kinase inhibitor 2A (CDKN2A), and mutL
homolog 1 (MLH1)[ 72]. Similar results have been described
in hepatocarcinoma, lung cancer and gastric carcinoma,
although different indicator genes were used [83–85].
Dnmt3b is Post-Transcriptionally Regulated
The reasons for the observed overexpression of Dnmt3b in
some cancers are largely unknown. On the level of gene
transcription alterations of the primary DNA sequence,
such as gene amplification or activating mutations, are as
reasonable to consider as potential trans-acting mecha-
nisms, e.g. increased expression of transcription factors.
Indeed, several polymorphisms were detected in the
DNMT3B gene promoter which increases the risk of
developing lung cancer, colorectal cancer, prostate cancer,
and breast cancer [86–90]. In lung cancer the observed
C  >T transition led to enhanced DNMT3B promoter
activity, providing one explanation for elevated DNMT3B
transcript levels in this tumor entity [86]. Despite, there is
increasing evidence that Dnmt3b expression may be more
relevantly regulated on the post-transcriptional level. The 3′
UTRs of the DNMT3A and DNMT3B mRNA contain
complementary sites for the recently detected miR-29
family. Fabbri and colleagues could show that miR-29a,
miR-29b and miR-29c bind to the predicted target sequence
in lung cancer cell lines, leading to a decrease of Dnmt3b
protein levels in the cytoplasm of transfected cells [91].
Important to note, expression of the miR-29 family is
commonly downregulated in lung cancer [92, 93]. Enforced
expression of miR-29 in lung cancer cell lines restored
normal patterns of DNA methylation accompanied by a
decrease of tumorigenicity of these cells, as shown by in
vitro and in vivo mouse xenograft models [91]. Knowing
that miRNA profiles are globally downregulated in breast
cancer [22], there is reason to argue that miRNAs targeting
DNMT3B mRNA may also be affected by downregulation,
resulting in increased transcript levels of the gene (Fig. 1).
Another study recently uncovered a further mechanism
of post-transcriptional regulation of Dnmt3b expression.
The human family of embryonic-lethal, abnormal vision
(ELAV)-like proteins contains four members, of which only
Hu-antigen R (HuR) is expressed ubiquitously in many cell
types [94]. HuR protein possesses three RNA-recognition
motifs by which it binds target mRNAs bearing AU- and U-
rich sequences, leading to enhanced stability and decreased
decay of the transcript [95, 96]. HuR has become
recognized as a pivotal regulator of gene expression, whose
function was found to be impaired in many tumor entities. In
ovarian carcinoma, HuR was reported as being overexpressed
together with one of its target genes, cyclooxegenase-2
(COX2). Moreover, high expression of HuR was shown to
be a prognostic factor in patient survival [97]. So far, most
studies on HuR expression and function focussed on breast
and colon cancer. In breast cancer, a global change in HuR-
bound mRNAs is implicated in the evolution of a more
tumorigenic phenotype and tumor progression [98]. HuR is
overexpressed in 29–39% of breast carcinomas, which
correlates with increased Cox-2 expression and adverse
survival of the patient [99–101]. Moreover, cytoplasmic
HuR accumulation could be identified as a significant factor
of tamoxifen resistance in estrogen receptor positive breast
cancer cell lines [102]. HuR overexpression mediated
decreased tamoxifen sensitivity in these cells, while decreas-
ing the levels of HuR increased tamoxifen sensitivity.
Moreover, high HuR expression levels were associated with
tamoxifen responsiveness and advanced tumor grade also in
primary breast carcinomas, arguing for a role of HuR target
mRNAs in the acquisition of resistance to anti-hormonal
therapy. Further evidence of a role of HuR in tumor biology
was provided from studies in colon cancer. There, HuR was
described as being increasingly expressed in consecutive
stages of the adenoma-carcinoma sequence, whereas HuR
expression in normal mucosa was low and infrequent. [103].
High HuR expression in colon cancer, similar to breast
cancer, was an independent predictor of adverse patient
survival [104], largely attributable to its tumorigenic pheno-
type which was increased in mouse xenograft models after
enforced overexpression, and decreased after HuR-based
antisense approaches [105].
Interestingly, besides many important proto-oncogenes,
like FOS, MYC, COX2, CCND1 or CTNNB1 [105–108],
DNMT3B mRNAwas identified as a putative HuR target in
an en masse approach, in which one HuR binding motif
was computationally detected in the DNMT3B 3′UTR
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function was further characterized in colorectal carcinoma
RKO cells. In immunoprecipitation assays, Lopez de
Silanes and colleagues showed for the first time that
DNMT3B mRNA co-precipitates with HuR protein under
conditions that preserved the HuR-mRNA complex [109].
After siRNA-mediated silencing of HuR expression,
DNMT3B mRNA levels were reduced by 25%. In order to
test whether this reduction was due to changes in mRNA
stability and to exclude a possible change on the level of
transcription, the authors inhibited de novo transcription in
RKO cells by means of actinomycin D, and then monitored
DNMT3B mRNA levels over time. Indeed, cells in which
HuR expression has been silenced by siRNA showed a
substantial decrease of DNMT3B transcript halftime as
compared to control cells. Therefore, HuR binding to its
target was responsible for DNMT3B mRNA stability in
cancerous cells. Furthermore, when HuR levels were
lowered in RKO cells this was associated with a decrease
of the global DNA methylation content as well as with a
decrease of methylation in two indicator DNA regions, the
pericentromeric Sat2 and the subtelomeric D4Z4 sequence.
These regions were shown to be specifically hypometh-
ylated when a certain mutation in the DNMT3B gene
occurs, which is associated with the rare autosomal ICF
syndrome [41]. In summary, it was proven that the
association of HuR with DNMT3B mRNA possibly
influences its expression on the level of transcript stabili-
zation, which effects global DNA methylation content as
well as Dnmt3b-specific methylation sites (Fig. 1).
Another interesting point in terms of post-transcriptional
regulation of DNMT3B mRNA is that of its occupation with
trans-acting regulatory factors in the 3′UTR. HuR was
shown to bind at least three different regions within the 3′
UTR of DNMT3B mRNA, consistent with studies on other
HuR targets like CYCS (cytochrome c) and DUSP1 (MAP
kinase phosphatase 1), which contain three and two different
binding regions for HuR, respectively [96, 109, 110]. The
reason for this is currently unknown, but it is assumed that
the presence of several HuR binding sites in the 3′UTR
increases the accessibility of the target sequence even in the
presence of other competing RNA-binding factors. For
instance, the three HuR binding motifs in the DUSP1
mRNA 3′UTR were shown to be bound by the translational
inhibitor TIAR [96]. TIAR and a further translational
inhibitor termed AUF1 were found to bind to the DNMT3B
3′UTR, too, [109, 111], although it remains to be determined
if the HuR recognition motifs were the actual site of binding.
However, upon induction of cellular stress, for instance by
treatment with the drug cisplatin, HuR and AUF1 dissociate
from the DNMT3B transcript, whereas the binding of TIAR
to the 3′UTR was found to be even tighter [109]. It is
possible that such changes in binding patterns at regulatory
regions of mRNA as a response to external stimuli is a key
to fast and efficient adaption of gene expression. In germ cell
development, the absence of Dnmt3b protein despite the
presence of its transcripts is a strong indicator of a regulatory
level downstream from gene transcription [112].
Further complexity in post-transcriptional regulation of
DNMT3B expression adds from the finding that members of
Figure 1 Schematic representation of factors that potentially influ-
ence abundance of the de novo methyltransferase Dnmt3b in tumorous
cells. In normal cells (left), physiological DNMT3B transcript levels
are maintained by inhibitory miR-29 (a–c), miR-148 and translational
inhibitor AUF1, which co-resides with the stabilization factor HuR in
the 3′UTR of the mRNA. In tumorous cells (right), miR-29 and miR-
148 are frequently abolished. Elevated levels of HuR may occupy the
3′UTR, thus preventing the binding of translational inhibitors. In the
nucleus, Dnmt3b activity is further stimulated by binding of the
catalytically inactive Dnmt3L as well as products from DNMT3B
splice variants and aberrantly truncated Dnmt3b proteins (asterisks).
Green color indicates stimulation/activation; red color indicates
inhibition. Open circles, unmethylated DNA; filled circles, methylated
DNA. For references see text.
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UTR in lung cancer cells, most probably competing with
other regulatory factors for binding mRNA within this
region [91]. Since the miR-29 family was reported to be
downregulated in lung cancer, the loss of a translational
inhibitor may ease the accessibility of the 3′UTR for other
stabilizing factors. Recently, a further miRNA was detected
to target the DNMT3B transcript. Duursma et al. reported
that, in contrast to the current knowledge on miRNA
biology, miR-148 does not target the 3′UTR of the
DNMT3B mRNA but its coding sequence (CDS), leading
do decreased expression level of the DNMT3B transcript
[113]. The binding of miRNAs to the CDS is a common
mechanism in plants [114], but was functionally not
detected in animals yet. So far, targeting of CDS by
miRNAs in animals has only been hypothesized based on
bioinformatics approaches. Interestingly, the CDS region
that is targeted by miR-148 is evolutionary conserved and
present in the splice variants DNMT3B1, DNMT3B2, and
DNMT3B4, but not in the most abundantly expressed
transcript of DNMT3B3, indicating that the DNMT3B3
variant is resistant to regulation by miR-148. In two tumor
entities miR-148 expression was recently reported to be
downregulated. In primary gastric cancers miR-148 as well
as miR128b and miR-129 were downregulated as compared
to normal gastric tissue [115]. Also in primary breast
carcinoma samples Lehmann and colleagues reported the
downregulation of a panel of miRNAs, including miR-148
[116]. Furthermore, these authors found that the DNA
sequence encoding miR-148 is a target of hypermethyla-
tion, leading to the observed expression loss of this miRNA
species. This finding adds an interesting aspect to the link
between DNMT expression and aberrant DNA hyper-
methylation, because it may be possible that elevated
Dnmt3b expression in cancer may be, at least in part,
initiated, maintained or increased by hypermethylation of
genes encoding Dnmt3b-repressive factors. Recapitulating
the idea that various regulatory factors compete in binding to
target sequences of the DNMT3B gene, even minor shifts in
the dynamics of these factors together with a altered pattern
of various splice variants, e.g. through hypermethylation of
potential repressor genes, represents the most probable
explanation to date for the increased expression and activity
of methyltransferases observed in human cancer.
MicroRNAs and Breast Cancer
MiRNAs have been shown to play a critical role in the
regulation of a wide range of biological and pathological
processes. Recent large-scale profiling approaches have
revealed that miRNAs are globally downregulated in
several cancer types, including breast cancer (for overview
see Table 1). The first study describing genome-wide
profiling of miRNAs in breast cancer identified 29
differentially expressed candidates, of which 15 predictive
miRNAs were able to distinguish between breast cancer
and normal breast tissue [22]. In addition, several correla-
tions between downregulation of certain miRNAs and
clinicopathological features, such as ER/PgR positivity,
tumor size, lymph node status and the expression of p53
were found. In particular the expression loss of members of
the let-7 family was associated with clinical features, such
as PgR status (let-7c), a positive lymph node status (let-7f-
1, let-7a-3 and let-7a-2), or a high proliferation index (let-
7c and let-7d). Moreover, panels of miRNAs in breast
carcinomas characteristic for the Her2/neu or ER status of
the analyzed tumor have been detected [117]. There is now
increasing evidence that signatures of miRNA expression
may not only be used in the future as tumor biomarkers for
diagnosis and patient risk stratification, but since hyper-
methylation was identified as an important mechanism of
miRNA silencing, deregulated miRNAs may also represent
novel targets for an anticancer therapy. In an approach
taking advantage of disruption of the DNMT1 and
Table 1 Differentially expressed miRNAs in human breast cancer.
Name Proposed target genes Reference
Downregulated
a
miR-9-1 – [116]
miR-29a-c DNMT3A, DNMT3B [91]
miR-148 DNMT3B [113]
Downregulated
b
let-7 RAS [19]
miR-15/16 BCL2 [122]
miR-17-5p AIB1 [123]
miR-27b CYPB1 [124]
miR-125a/b HER2, HER3 [125]
miR-126 p85β [126, 127]
miR-130a GAX, HOXA5 [128]
miR-143 ERK5 [129]
miR-145 MAP3K3, MAP4K4, CBFB [22]
miR-155 SOCS1, APC [22]
miR-200c TCF8 [130]
miR-205 HER3 [131]
miR-335 PTPRN2, MERTK, SOX4 [126]
Upregulated
b
miR-10b HOXD10 [132]
miR-18a KRAS [123]
miR-21 TPM1, PDCD4 [23]
miR-27a ZBTB10 [132]
miR-206 ER-α [92]
amiRNAs silenced by or involved in epigenetic mechanisms
bmiRNAs deregulated by genetic or undetermined mechanisms
12 J Mammary Gland Biol Neoplasia (2010) 15:5–17DNMT3B gene in colon cancer cells (so-called double-
knock out cells, DKO), CpG hypermethylation was
identified as one important mechanism leading to a global
loss of miRNA expression [27], mostly affecting those
species that exhibit tumor suppressive functions (reviewed
in [118]). Since generally, DNA hypermethylation is a
reversible process e.g. by inhibitors of DNMTs, this drug
class may also potentially revert a part of epigenetically
silenced miRNAs in cancer diseases.
Recently, evidence was shown that miRNAs, besides
aberrant DNA methylation, may also be deregulated due to
copy number variations. One study describing differential
expression patterns of miRNAs in breast cancer also
investigated its expression changes in relation to chromo-
somal localization. Interestingly, the authors found several
miR candidates that reside in chromosomal regions which
are either frequently deleted or amplified in breast cancer,
e.g. downregulation of miR-125b in the frequently deleted
region 11q-23-24, or overexpression of miR-21 in 17q23,
which is commonly amplified in breast cancer [22]. Further-
more, a study applying CGH arrays on different epithelial
tumors demonstrated that 73% of miRNA genes in breast
cancer reside in genomic regions affected by copy number
variations [119], providing a further possible explanation for
differential miRNA profiles in tumor tissues.
Another mechanism by which miRNA profiles may be
altered in tumors lies within abnormalities in the miRNA
processing machinery. It was the same study that observed
significant changes in expression of Dicer and AGO1, both
being involved in miRNA maturation processes [119]. In
ovarian cancer, DICER1 isoverexpressedin correlationwith
copy number gain in 25% of cases, and overexpression of
AGO1isattributabletogeneamplificationin52%oftumors.
A further defect in miRNA processing enzymes was recently
described by Melo and colleagues. In this study the authors
investigated mutational alterations in several genes of the
miRNA processing machinery [120], including DICER1,
DROSHA, DGCR8, TRPB, AGO1, AGO2, and AGO4.I n
microsatellite instable colorectal cancer they detected trun-
cating frameshift mutations in TARBP2, encoding a member
of the Dicer-containing complex [121]. TARBP2 mutant
cells exhibited a 90% reduced efficiency of endogenous
miRNA processing, and re-introduction of the wild-type
protein restored processing capacity to normal levels.
Moreover, the loss of functional TARBP2 protein also
affected the expression of Dicer as a secondary effect, since
Dicer expression was substantially reduced in the TARBP2-
mutant, whereas its expression was restored after re-
expression of the wild-type TARBP2 protein. Decreased
Dicer expression was recently observed in breast cancer,
where loss of expression represented an independent
prognostic factor in the metastatic disease, and reduced
expression of Dicer was associated with the highly
aggressive mesenchymal phenotype [28]. Whether genetic
lesions like TARBP2 mutations in colorectal cancer also
account for impaired miRNA processing in breast cancer
remains to be determined in future studies. It is, however,
conclusive that besides DNA hypermethylation of miRNA
genes, structural genetic alterations also contribute to the
observed dramatic changes of miRNA expression profiles
in human cancer.
Concluding Remarks
In cancer research, our knowledge on hypermethylated DNA
sequences encoding either proteins or miRNAs has signifi-
cantly increased over the last decade. Yet, the precise
mechanisms initiating hypermethylation during tumor devel-
opment and progression are still not clear. Apparently, cancer
cellsacquireacomplexpatternofgeneticaswellasepigenetic
lesions, which most intriguingly may even become inter-
connected. One example is the hypermethylation of DNA
repair genes, such as BRCA1 or MLH1, which favors the
acquisition of further structural DNA lesions in the trans-
formed cell. Conversely, structural aberrations in the
DNMT3B gene, may be partly responsible for increased
Dnmt3b expression and consequently hypermethylation of
critical genes in human tumors. Adding complexity to this,
such specific genetic-epigenetic relations may not necessarily
befoundinalltumortypes:BRCA1 methylation, for instance,
is observed in breast and ovarian cancer only, but almost
absent in any other cancer type. Further investigations are
needed in order to unravel the question of how the hyper-
methylome is established and maintained in a cancer cell.
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